When I stay on schedule, I take a cocktail of fisetin, quercetin, theaflavin, apigenin, and some aids to assimilation every month or so for a 2-3 day run. If this sounds loose, it is because I have never fully committed to the practice or the underlying research. When I took the cocktail this time, it had been several months since doing so. Within eight hours, I experienced a profound sense of fatigue that took several days to dissipate.
The experience could have been coincidental; perhaps I was shaking off a minor virus. Has anyone else had this experience when attempting to reduce their population of senolytic cells hanging around?
I perform senolytic interventions much less frequently nowadays. When I first initiated senolytic therapy in spring 2019, I experienced a pronounced reduction in low‑grade (“cold”) inflammation. Over time I experimented with several protocols and compound combinations. The most effective regimen consisted of fisetin combined with piperlongumine, quercetin, and theaflavins.
As the magnitude of the response has diminished—possibly due to concurrent use of rapamycin or taurine—I now limit senolytic sessions to approximately three times per year.